Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation

• Published in: Biomedical Journal Vol. 47; no. 3; p. 100696
• Main Authors: Su, Yung-Yeh, Chiang, Nai-Jung, Chiu, Tai-Jan, Huang, Chien-Jui, Hsu, Shao-Jung, Lin, Hsin-Chen, Yang, Shih-Hung, Yang, Youngsen, Chou, Wen-Chi, Chen, Yen-Yang, Bai, Li-Yuan, Li, Chung-Pin, Chen, Jen-Shi
• Format: Journal Article
• Language: English
• Published: United States Elsevier B.V 01.06.2024; Chang Gung University; Elsevier
• Subjects: Chemotherapy; Humans; Neoadjuvant therapy; Pancreatic cancer; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - therapy; Postoperative adjuvant chemotherapy; Review; Societies, Medical; Taiwan; Taiwan; Postoperative adjuvant chemotherapy; Neoadjuvant therapy; Chemotherapy; Pancreatic cancer
• ISSN: 2319-4170; 2320-2890; 2320-2890
• DOI: 10.1016/j.bj.2023.100696

Pancreatic cancer is a highly aggressive malignancy with a poor prognosis. Over the past decade, significant therapeutic advancements have improved the survival rates of patients with pancreatic cancer. One of the primary factors contributing to these positive outcomes is the evolution of chemotherapy, from monotherapy to doublet or triplet regimens, and the integration of multimodal approaches. Additionally, targeted agents tailored to patients with specific genetic alterations and the development of cell therapies show promise in benefiting certain subpopulations. This article focuses on examining pivotal studies that explore the role of chemotherapy in neoadjuvant, adjuvant, maintenance, and salvage settings; highlights interesting findings related to cell therapy; and provides an overview of ongoing trials concerning metastatic settings. This review primarily aimed to offer recommendations based on therapeutic evidence, recent advancements in new treatment combinations, and the most innovative approaches. A unique aspect of this review is the inclusion of published papers on clinical trials and real-world data in Taiwan, thus adding a valuable perspective to the overall analysis. •A multidisciplinary team approach is necessary for patient's assessment before treatment.•This article includes Taiwan's own study results for Taiwan oncologists references, providing the current update worldwide chemotherapeutic treatment studies in pancreatic cancer with different settings.•Genetic profile is a novel way to guide further treatment•Clinical trials are encouraged for patients with pancreatic cancer.